249 related articles for article (PubMed ID: 29939289)
21. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Bornholdt ZA; Herbert AS; Mire CE; He S; Cross RW; Wec AZ; Abelson DM; Geisbert JB; James RM; Rahim MN; Zhu W; Borisevich V; Banadyga L; Gunn BM; Agans KN; Wirchnianski AS; Goodwin E; Tierney K; Shestowsky WS; Bohorov O; Bohorova N; Velasco J; Ailor E; Kim D; Pauly MH; Whaley KJ; Alter G; Walker LM; Chandran K; Zeitlin L; Qiu X; Geisbert TW; Dye JM
Cell Host Microbe; 2019 Jan; 25(1):49-58.e5. PubMed ID: 30629918
[TBL] [Abstract][Full Text] [Related]
22. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
23. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of broad ebolavirus neutralization by a human survivor antibody.
West BR; Wec AZ; Moyer CL; Fusco ML; Ilinykh PA; Huang K; Wirchnianski AS; James RM; Herbert AS; Hui S; Goodwin E; Howell KA; Kailasan S; Aman MJ; Walker LM; Dye JM; Bukreyev A; Chandran K; Saphire EO
Nat Struct Mol Biol; 2019 Mar; 26(3):204-212. PubMed ID: 30833785
[TBL] [Abstract][Full Text] [Related]
25. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.
Martinez O; Tantral L; Mulherkar N; Chandran K; Basler CF
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S825-32. PubMed ID: 21987758
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
Dean CL; Hooper JW; Dye JM; Zak SE; Koepsell SA; Corash L; Benjamin RJ; Kwilas S; Bonds S; Winkler AM; Kraft CS
Transfusion; 2020 May; 60(5):1024-1031. PubMed ID: 32129478
[TBL] [Abstract][Full Text] [Related]
27. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.
Schoeder CT; Gilchuk P; Sangha AK; Ledwitch KV; Malherbe DC; Zhang X; Binshtein E; Williamson LE; Martina CE; Dong J; Armstrong E; Sutton R; Nargi R; Rodriguez J; Kuzmina N; Fiala B; King NP; Bukreyev A; Crowe JE; Meiler J
PLoS Pathog; 2022 May; 18(5):e1010518. PubMed ID: 35584193
[TBL] [Abstract][Full Text] [Related]
28. Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines.
Felgner J; Clarke E; Hernandez-Davies JE; Jan S; Wirchnianski AS; Jain A; Nakajima R; Jasinskas A; Strahsburger E; Chandran K; Bradfute S; Davies DH
Antiviral Res; 2024 May; 225():105851. PubMed ID: 38458540
[TBL] [Abstract][Full Text] [Related]
29. Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.
Olejnik J; Forero A; Deflubé LR; Hume AJ; Manhart WA; Nishida A; Marzi A; Katze MG; Ebihara H; Rasmussen AL; Mühlberger E
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331091
[TBL] [Abstract][Full Text] [Related]
30. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
31. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
32. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses.
Milligan JC; Davis CW; Yu X; Ilinykh PA; Huang K; Halfmann PJ; Cross RW; Borisevich V; Agans KN; Geisbert JB; Chennareddy C; Goff AJ; Piper AE; Hui S; Shaffer KCL; Buck T; Heinrich ML; Branco LM; Crozier I; Holbrook MR; Kuhn JH; Kawaoka Y; Glass PJ; Bukreyev A; Geisbert TW; Worwa G; Ahmed R; Saphire EO
Cell; 2022 Mar; 185(6):995-1007.e18. PubMed ID: 35303429
[TBL] [Abstract][Full Text] [Related]
33. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
Rimoin AW; Lu K; Bramble MS; Steffen I; Doshi RH; Hoff NA; Mukadi P; Nicholson BP; Alfonso VH; Olinger G; Sinai C; Yamamoto LK; Ramirez CM; Okitolonda Wemakoy E; Kebela Illunga B; Pettitt J; Logue J; Bennett RS; Jahrling P; Heymann DL; Piot P; Muyembe-Tamfum JJ; Hensley LE; Simmons G
J Infect Dis; 2018 Jan; 217(2):223-231. PubMed ID: 29253164
[TBL] [Abstract][Full Text] [Related]
34. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
[TBL] [Abstract][Full Text] [Related]
35.
Woolsey C; Borisevich V; Agans KN; Fenton KA; Cross RW; Geisbert TW
mBio; 2021 Aug; 12(4):e0151721. PubMed ID: 34372693
[TBL] [Abstract][Full Text] [Related]
36. Development of an antibody cocktail for treatment of Sudan virus infection.
Herbert AS; Froude JW; Ortiz RA; Kuehne AI; Dorosky DE; Bakken RR; Zak SE; Josleyn NM; Musiychuk K; Jones RM; Green B; Streatfield SJ; Wec AZ; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Whaley KJ; Stonier SW; Bornholdt ZA; Chandran K; Zeitlin L; Sampey D; Yusibov V; Dye JM
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3768-3778. PubMed ID: 32015126
[TBL] [Abstract][Full Text] [Related]
37. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study.
Diallo MSK; Ayouba A; Keita AK; Thaurignac G; Sow MS; Kpamou C; Barry TA; Msellati P; Etard JF; Peeters M; Ecochard R; Delaporte E; Toure A;
Lancet Microbe; 2021 Dec; 2(12):e676-e684. PubMed ID: 35544108
[TBL] [Abstract][Full Text] [Related]
38. Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop.
Murin CD; Bruhn JF; Bornholdt ZA; Copps J; Stanfield R; Ward AB
Cell Rep; 2018 Sep; 24(10):2723-2732.e4. PubMed ID: 30184505
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans.
Rijal P; Elias SC; Machado SR; Xiao J; Schimanski L; O'Dowd V; Baker T; Barry E; Mendelsohn SC; Cherry CJ; Jin J; Labbé GM; Donnellan FR; Rampling T; Dowall S; Rayner E; Findlay-Wilson S; Carroll M; Guo J; Xu XN; Huang KA; Takada A; Burgess G; McMillan D; Popplewell A; Lightwood DJ; Draper SJ; Townsend AR
Cell Rep; 2019 Apr; 27(1):172-186.e7. PubMed ID: 30943399
[TBL] [Abstract][Full Text] [Related]
40. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
Howell KA; Qiu X; Brannan JM; Bryan C; Davidson E; Holtsberg FW; Wec AZ; Shulenin S; Biggins JE; Douglas R; Enterlein SG; Turner HL; Pallesen J; Murin CD; He S; Kroeker A; Vu H; Herbert AS; Fusco ML; Nyakatura EK; Lai JR; Keck ZY; Foung SKH; Saphire EO; Zeitlin L; Ward AB; Chandran K; Doranz BJ; Kobinger GP; Dye JM; Aman MJ
Cell Rep; 2016 May; 15(7):1514-1526. PubMed ID: 27160900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
